These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38701024)

  • 21. FDA approves Merck & Co's pulmonary arterial hypertension drug sotatercept.
    Kingwell K
    Nat Rev Drug Discov; 2024 May; 23(5):327. PubMed ID: 38538881
    [No Abstract]   [Full Text] [Related]  

  • 22. Connecticut Medicine roundtable: Comparative Effectiveness Public Advisory Council (CEPAC).
    Deren MM
    Conn Med; 2012 Apr; 76(4):243-5. PubMed ID: 22611726
    [No Abstract]   [Full Text] [Related]  

  • 23. Pulmonary arterial hypertension specific therapy: The old and the new.
    Zolty R
    Pharmacol Ther; 2020 Oct; 214():107576. PubMed ID: 32417272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017.
    Ollivier C; Sun H; Amchin W; Beghetti M; Berger RMF; Breitenstein S; Garnett C; Gullberg N; Hassel P; Ivy D; Kawut SM; Klein A; Lesage C; Migdal M; Nije B; Odermarsky M; Strait J; de Graeff PA; Stockbridge N
    J Am Heart Assoc; 2019 May; 8(10):e011306. PubMed ID: 31088189
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of hypertension 1996. Effectiveness, tolerance, cost-benefit aspects].
    Rahn KH
    Med Klin (Munich); 1996 Jun; 91(6):380-3. PubMed ID: 8767312
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pulmonary arterial hypertension from the risk assessment to combined treatment].
    Santos-Martínez LE; Moreno-Ruiz LA; Cabrera-Ramírez C; Mendoza-Pérez BC; Galván-Oseguera H; Magaña-Serrano JA; Lupercio-Mora K; Saturno-Chiu G
    Rev Med Inst Mex Seguro Soc; 2019 Sep; 57(5):314-323. PubMed ID: 32568487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unsolved Issues on Beneficial Effects of Combination Therapy With Sotatercept in Pulmonary Arterial Hypertension.
    Benincasa G; Strozziero MG; Trama U; Napoli C
    Heart Lung Circ; 2024 Jan; 33(1):12-13. PubMed ID: 38040502
    [No Abstract]   [Full Text] [Related]  

  • 28. Win Statistics in Pulmonary Arterial Hypertension Clinical Trials.
    Weatherald J; Moutchia J; Al-Naamani N; McClelland RL; Ventetuolo CE; Palevsky HI; Harhay MO; Kawut SM
    Am J Respir Crit Care Med; 2023 Dec; 208(11):1231-1234. PubMed ID: 37734029
    [No Abstract]   [Full Text] [Related]  

  • 29. Epoprostenol and Treprostinil: Differential Effects on Regulatory T-Cell Generation in Patients with Pulmonary Arterial Hypertension.
    Yasuma T; Fujimoto H; D'Alessandro-Gabazza CN; Gabazza EC; Hataji O; Kobayashi T
    Am J Respir Crit Care Med; 2023 Dec; 208(11):1248. PubMed ID: 37774405
    [No Abstract]   [Full Text] [Related]  

  • 30. Treating pulmonary arterial hypertension: is it worth it?
    Gibbs JS
    Heart; 2010 Oct; 96(20):1607-8. PubMed ID: 20937746
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study.
    Ma W; Sun N; Duan C; Zhao L; Hua Q; Sun Y; Dang A; Gao P; Qu P; Cui W; Zhao L; Dong Y; Cui L; Qi X; Jiang Y; Xie J; Li J; Wu G; Du X; Huo Y; Chen P;
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):41-50. PubMed ID: 32915349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 33. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epoprostenol therapy for pulmonary arterial hypertension: the first Polish experience.
    Kopeć G; Waligóra M; Jonas K; Stępniewski J; Magoń W; Podolec P
    Pol Arch Intern Med; 2019 Jan; 129(1):65-68. PubMed ID: 30543197
    [No Abstract]   [Full Text] [Related]  

  • 35. The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension.
    Botros L; Szulcek R; Jansen SMA; Kurakula K; Goumans MTH; van Kuilenburg ABP; Vonk Noordegraaf A; de Man FS; Aman J; Bogaard HJ
    Am J Respir Crit Care Med; 2020 Jul; 202(2):296-299. PubMed ID: 32275837
    [No Abstract]   [Full Text] [Related]  

  • 36. Opportunities to improve the cost-effectiveness of treatment for hypertension.
    Prichard BN
    Pharmacoeconomics; 1992 Mar; 1(3):219-21. PubMed ID: 10147110
    [No Abstract]   [Full Text] [Related]  

  • 37. The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
    Wright AC; Lin GA; Whittington MD; Agboola F; Herron-Smith S; Rind D; Pearson SD
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1078-1083. PubMed ID: 37610113
    [No Abstract]   [Full Text] [Related]  

  • 38. PHARMAC responds on treatments for pulmonary arterial hypertension.
    Metcalfe S; Rasiah D; Dougherty S
    N Z Med J; 2005 Dec; 118(1227):U1805. PubMed ID: 16372041
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
    Demerouti EA; Karyofyllis P; Apostolopoulou SC
    Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Costs vs. benefit: How much combination therapy of pulmonary arterial hypertension can we afford to pay?].
    Grünig E
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S176. PubMed ID: 19718610
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.